BR0209957A - Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade - Google Patents
Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidadeInfo
- Publication number
- BR0209957A BR0209957A BR0209957-8A BR0209957A BR0209957A BR 0209957 A BR0209957 A BR 0209957A BR 0209957 A BR0209957 A BR 0209957A BR 0209957 A BR0209957 A BR 0209957A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- obesity
- arthritis
- diabetes
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 208000008589 Obesity Diseases 0.000 title abstract 3
- 206010003246 arthritis Diseases 0.000 title abstract 3
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 235000020824 obesity Nutrition 0.000 title abstract 3
- 208000030814 Eating disease Diseases 0.000 title abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 title abstract 2
- 235000014632 disordered eating Nutrition 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000011321 prophylaxis Methods 0.000 title 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010062237 Renal impairment Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112370 | 2001-05-21 | ||
| PCT/EP2002/005120 WO2002094789A1 (en) | 2001-05-21 | 2002-05-08 | Quinoline derivatives as ligands for the neuropeptide y receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0209957A true BR0209957A (pt) | 2004-03-30 |
Family
ID=8177497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0209957-8A BR0209957A (pt) | 2001-05-21 | 2002-05-08 | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6818767B2 (enExample) |
| EP (1) | EP1395564B1 (enExample) |
| JP (1) | JP3715280B2 (enExample) |
| KR (1) | KR100621287B1 (enExample) |
| CN (1) | CN100376557C (enExample) |
| AR (1) | AR035979A1 (enExample) |
| AT (1) | ATE387428T1 (enExample) |
| AU (1) | AU2002338896B2 (enExample) |
| BR (1) | BR0209957A (enExample) |
| CA (1) | CA2446324A1 (enExample) |
| DE (1) | DE60225274T2 (enExample) |
| ES (1) | ES2300478T3 (enExample) |
| GT (1) | GT200200090A (enExample) |
| MX (1) | MXPA03010565A (enExample) |
| PA (1) | PA8545301A1 (enExample) |
| PE (1) | PE20021155A1 (enExample) |
| UY (1) | UY27300A1 (enExample) |
| WO (1) | WO2002094789A1 (enExample) |
| ZA (1) | ZA200308783B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
| JP2005519876A (ja) * | 2001-11-27 | 2005-07-07 | メルク エンド カムパニー インコーポレーテッド | ２−アミノキノリン化合物 |
| MXPA04007502A (es) | 2002-02-04 | 2004-11-10 | Hoffmann La Roche | Derivados de quinolina como antagonistas de neuropeptido y (npy). |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| RU2296757C2 (ru) | 2002-07-05 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | Производные хиназолина |
| BR0313278A (pt) | 2002-08-07 | 2005-07-05 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo e sua utilização, método para o tratamento e profilaxia de enfermidades e obesidade e utilização dos compostos |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2006519846A (ja) * | 2003-03-10 | 2006-08-31 | シェーリング コーポレイション | 複素環式キナーゼインヒビター：使用および合成の方法 |
| JP4765627B2 (ja) | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| JP2007510745A (ja) | 2003-11-10 | 2007-04-26 | シンタ ファーマシューティカルズ コーポレーション | 縮合複素環式化合物 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
| RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
| WO2007018248A1 (ja) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | ピリドン化合物 |
| CA2619770A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
| US20090264426A1 (en) | 2005-09-07 | 2009-10-22 | Shunji Sakuraba | Bicyclic aromatic substituted pyridone derivative |
| EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
| US8158791B2 (en) | 2005-11-10 | 2012-04-17 | Msd K.K. | Aza-substituted spiro derivatives |
| WO2008020302A2 (en) * | 2006-08-17 | 2008-02-21 | Pfizer Products Inc. | Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors |
| US20090247560A1 (en) | 2006-09-28 | 2009-10-01 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
| JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Ｍｓｄ株式会社 | インドールジオン誘導体 |
| WO2008141077A1 (en) * | 2007-05-10 | 2008-11-20 | Janssen Pharmaceutica N.V. | Process for the preparation of tetrahydroquinolinyl, benzoxazine and benzothiazine derivatives |
| PT2182950T (pt) | 2007-05-17 | 2017-09-11 | Helperby Therapeutics Ltd | Uso de compostos 4-(pirrolidin-1-il)quinolina para eliminação de microrganismos clinicamente latentes |
| WO2008150940A1 (en) * | 2007-06-01 | 2008-12-11 | E. I. Du Pont De Nemours And Company | Chrysenes for green luminescent applications |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8034782B2 (en) | 2008-07-16 | 2011-10-11 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| SI2220076T1 (sl) * | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| KR20100097156A (ko) | 2007-11-16 | 2010-09-02 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| US20110015181A1 (en) | 2008-03-06 | 2011-01-20 | Makoto Ando | Alkylaminopyridine derivative |
| US20110015198A1 (en) | 2008-03-28 | 2011-01-20 | Banyu Pharmaceutical Co., Inc. | Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2727914A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diaryl ketoxime derivative technical field |
| AU2009277736A1 (en) | 2008-07-30 | 2010-02-04 | Banyu Pharmaceutical Co., Ltd. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| PH12013501686A1 (en) | 2011-02-25 | 2017-10-25 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| CN105764916B (zh) | 2013-06-05 | 2021-05-18 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| SG11202000248UA (en) | 2017-07-14 | 2020-02-27 | Innate Tumor Immunity Inc | Nlrp3 modulators |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU43730A1 (enExample) * | 1962-06-14 | 1963-07-13 | ||
| US3272824A (en) * | 1962-12-06 | 1966-09-13 | Norwich Pharma Co | 4-amino-6, 7-di(lower) alkoxyquinolines |
| US3812127A (en) * | 1966-10-31 | 1974-05-21 | Pfizer | 4-(quinolin-4-yl)piperazine-1-carboxylic acid esters |
| US4035367A (en) * | 1974-09-09 | 1977-07-12 | Sandoz, Inc. | Hydroxyalkyl-substituted-amino-quinolines |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035917C (en) | 1990-02-13 | 2001-10-02 | John L. Krstenansky | Stabilized sulfonate, sulfate, phosphonate and phosphate derivatives of hirudin |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| DK0882717T3 (da) * | 1996-10-01 | 2010-12-13 | Kyowa Hakko Kirin Co Ltd | Nitrogenholdige heterocykliske forbindelser |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE69916288T2 (de) | 1998-08-14 | 2005-03-24 | F. Hoffmann-La Roche Ag | Lipasehemmer und chitosan enthaltende arzneimittel |
| ATE293970T1 (de) | 1998-08-14 | 2005-05-15 | Hoffmann La Roche | Lipasehemmer enthaltende pharmazeutische zusammensetzungen |
| WO2001034764A2 (en) * | 1999-11-08 | 2001-05-17 | Cytion S.A. | Apparatus and methods for positioning and analyzing biological membranous objects |
| US6900226B2 (en) * | 2000-09-06 | 2005-05-31 | Hoffman-La Roche Inc. | Neuropeptide Y antagonists |
-
2002
- 2002-05-08 JP JP2002591462A patent/JP3715280B2/ja not_active Expired - Fee Related
- 2002-05-08 MX MXPA03010565A patent/MXPA03010565A/es active IP Right Grant
- 2002-05-08 CN CNB028104013A patent/CN100376557C/zh not_active Expired - Fee Related
- 2002-05-08 CA CA002446324A patent/CA2446324A1/en not_active Abandoned
- 2002-05-08 DE DE60225274T patent/DE60225274T2/de not_active Expired - Fee Related
- 2002-05-08 ES ES02771639T patent/ES2300478T3/es not_active Expired - Lifetime
- 2002-05-08 AT AT02771639T patent/ATE387428T1/de not_active IP Right Cessation
- 2002-05-08 AU AU2002338896A patent/AU2002338896B2/en not_active Ceased
- 2002-05-08 EP EP02771639A patent/EP1395564B1/en not_active Expired - Lifetime
- 2002-05-08 BR BR0209957-8A patent/BR0209957A/pt not_active IP Right Cessation
- 2002-05-08 KR KR1020037015121A patent/KR100621287B1/ko not_active Expired - Fee Related
- 2002-05-08 WO PCT/EP2002/005120 patent/WO2002094789A1/en not_active Ceased
- 2002-05-16 PA PA20028545301A patent/PA8545301A1/es unknown
- 2002-05-17 AR ARP020101836A patent/AR035979A1/es not_active Application Discontinuation
- 2002-05-17 PE PE2002000425A patent/PE20021155A1/es not_active Application Discontinuation
- 2002-05-20 US US10/151,505 patent/US6818767B2/en not_active Expired - Fee Related
- 2002-05-20 GT GT200200090A patent/GT200200090A/es unknown
- 2002-05-21 UY UY27300A patent/UY27300A1/es not_active Application Discontinuation
-
2003
- 2003-11-11 ZA ZA200308783A patent/ZA200308783B/en unknown
-
2004
- 2004-05-24 US US10/852,509 patent/US20050049413A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2446324A1 (en) | 2002-11-28 |
| EP1395564A1 (en) | 2004-03-10 |
| KR100621287B1 (ko) | 2006-09-13 |
| PE20021155A1 (es) | 2002-12-17 |
| US20020198194A1 (en) | 2002-12-26 |
| ATE387428T1 (de) | 2008-03-15 |
| US6818767B2 (en) | 2004-11-16 |
| US20050049413A1 (en) | 2005-03-03 |
| GT200200090A (es) | 2003-06-19 |
| JP2004536066A (ja) | 2004-12-02 |
| WO2002094789A1 (en) | 2002-11-28 |
| JP3715280B2 (ja) | 2005-11-09 |
| EP1395564B1 (en) | 2008-02-27 |
| AU2002338896B2 (en) | 2006-04-27 |
| PA8545301A1 (es) | 2003-01-24 |
| DE60225274T2 (de) | 2009-03-26 |
| ZA200308783B (en) | 2005-02-11 |
| KR20030096416A (ko) | 2003-12-24 |
| MXPA03010565A (es) | 2004-03-02 |
| UY27300A1 (es) | 2002-11-29 |
| ES2300478T3 (es) | 2008-06-16 |
| AR035979A1 (es) | 2004-07-28 |
| DE60225274D1 (de) | 2008-04-10 |
| CN1522249A (zh) | 2004-08-18 |
| CN100376557C (zh) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0209957A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende um composto, utilização desse composto e processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| BR0212929A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, utilização de compostos, e método para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, disfunção renal, distúrbios alimentares e obesidade | |
| BR0307441A (pt) | Compostos, processo para a preparação de um composto, composição farmacêutica, utilização desses compostos, método para o tratamento e profilaxia de enfermidades e método para o tratamento de obesidade | |
| BR0113710A (pt) | Compostos, processo para a preparação e utilização dos mesmos, composição farmacêutica, processo para o tratamento e profilaxia de artrite, enfermidades cardiovasculares, diabetes, insuficiência renal, distúrbios alimentares e obesidade | |
| BR0215312A (pt) | Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| BR0116605A (pt) | Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono | |
| BR0115045A (pt) | Compostos, processo para sua preparação, composição farmacêutica que compreende os mesmos, sua utilização, processo para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
| BR0307665A (pt) | Compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para o tratamento e/ou profilaxia de enfermidades associadas com dpp iv e utilização dos compostos | |
| BRPI0312464B8 (pt) | compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos | |
| BRPI0411713A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização | |
| BR0012590A (pt) | Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, e, métodos para tratamento ou profilaxia de dor ou desconforto, e para tratamento ou profilaxia de dor neuropática ou central | |
| BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
| BR0211119A (pt) | Composto, método de tratar um paciente que tenha, ou de prevenir um paciente de pegar, uma doença ou condição, uso de um composto, e, método para fabricar um composto | |
| BR0209774A (pt) | Pirimidinas inibidoras de cdk, sua preparação e aplicação como medicamento | |
| BR0314314A (pt) | Derivados do éter 4-pirrolidina-fenil-benzìlico | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0309012A (pt) | Uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BR0308108A (pt) | Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade | |
| BRPI0513058A (pt) | derivado de pirimidina ou um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de pirimidina ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| BR0312000A (pt) | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos | |
| BRPI0409498A (pt) | uso de um composto, formulação farmacêutica, composto, composição farmacêutica, e, processo para preparação de um composto | |
| BRPI0512335A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização | |
| BRPI0514133A (pt) | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 7A., E 8A. ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010. |